Patents by Inventor Elise C. Kohn

Elise C. Kohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6790936
    Abstract: The invention provides for proteins correlated with cellular resistance to carboxyamido-triazole (CAI) which have at least one Src homology 3 (SH3) binding domain, and functionally equivalent compounds.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: September 14, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
  • Patent number: 6057346
    Abstract: A class of calcium-response modification compounds is disclosed which inhibits the activation of retroviral LTR promoters, including the HIV-LTR. This class of compounds are used to delay or suppress the transition of a retroviral infection from a latent to a virulent condition, thereby ameliorating retrovirally caused diseases such as AIDS. The compounds are also useful in cancer treatment, allowing for coordinated therapeutic approaches to retroviral diseases and related cancers such as AIDS and Kaposi's Sarcoma. The compounds are also useful in standardizing in vitro assays of clinical and experimental importance.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: May 2, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Kevin L. Gardner
  • Patent number: 5981712
    Abstract: This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.
    Type: Grant
    Filed: July 25, 1997
    Date of Patent: November 9, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
  • Patent number: 5880129
    Abstract: A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: March 9, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
  • Patent number: 5744492
    Abstract: Angiogenesis is a composite of regulated proliferation and regulated invasion occuring in a variety of normal and pathologic conditions. Compound 1 and related analogs are useful for inhibiting angiogenesis in a host and offer a novel approach to the treatment of cancer, diabetic retinopathy, hemangiomata, vasculidities and other diseases associated with angiogenesis.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: April 28, 1998
    Assignee: United States of America
    Inventors: Elise C. Kohn, Lance A. Liotta, Riccardo Alessandro
  • Patent number: 5705514
    Abstract: A method of inhibiting the invasion and metastasis of malignant solid tumors in mammals, said method comprising administering to said mammal an anti-proliferative, anti-invasive and anti-metastasis effective amount of a compound selected from the group of formulas consisting of: ##STR1## wherein: p is an integer of from 0 to 4;Ar.sup.1 is a moiety selected from the group consisting of --Ar.sup.2 --X--Ar.sup.3, phenyl, trioxaadamantyl, anthracenyl, anthraquinonyl, naphthyl, phenanthryl, and substituted versions thereof;Ar.sup.2 and Ar.sup.3 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof;X is a linking moiety selected from the group consisting of O, S, SO.sub.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
  • Patent number: 5652223
    Abstract: This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: July 29, 1997
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
  • Patent number: 5602156
    Abstract: Calcium homeostasis is an important regulator of MMP-2 transcription, activation and activity. Disclosed herein are compounds which inhibit the expression of matrix metalloproteinases in cells. Pharmaceutical application of these compounds to inhibit the expression of MMPs offers a new approach to cancer treatment as well as treatment for nerve healing, degenerative cartilagenous diseases, decubitus ulcers, arthritis, Alzheimer's disease, wound healing, proliferative retinopathy, proliferative renal diseases, corneal ulcers and fertility problems.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: February 11, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta
  • Patent number: 5565478
    Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of formula I defined herein in combination with paclitaxel or other modified taxane analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: October 15, 1996
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Elise C. Kohn, Eddie Reed, Lance A. Liotta
  • Patent number: 5498620
    Abstract: A compound having the formula: ##STR1## and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 12, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
  • Patent number: 5482954
    Abstract: A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: January 9, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
  • Patent number: 5405782
    Abstract: The present invention relates to an improved method for the determination of therapeutic agents in blood. This method utilizes a solid phase extraction of the solute from plasma followed by reverse phase high performance liquid chromatography on a column of irregularly shaped C-18 modified silica. Comparison of the produced chromatogram with a standard curve provides a precise and accurate quantification of the amount of the solute in blood. Additionally, the extraction and chromatography steps can be readily automated for the rapid determination of multiple samples.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: April 11, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta
  • Patent number: 5359078
    Abstract: A compound having the formula:Y--(CH.sub.2).sub.p --Ar.sup.11 --X--Ar.sup.12wherein:p is an integer of from 0 to 4;Ar.sup.11 and Ar.sup.12 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof in which the substituents are members selected from the group consisting of halogen, nitro, carboxyl and alkoxy;X is a linking moiety selected from the group consisting of O, S, SO.sub.2, CO, CHCN, straight chain alkyl, alkoxy, and alkoxyalkyl; andY is a nitrogen-containing heterocyclic moiety.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: October 25, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
  • Patent number: 5132315
    Abstract: Tumor invasion and metastasis is the most life threatening aspect of cancer. Invasion and metastasis is a multistep process. Cellular functions required for invasion are attachment, locomotion and directed migration. Regulation of these processes may be independent of cell growth. A carboxylamino-imidazole compound was found to be potent inhibitor of tumor cell attachment, motility, invasion, proliferation, and metastasis. This compound and equivalents thereof constitute a cancer treatment agent of particular use in the treatment of peritoneal carcinomatosis of ovarian cancer.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: July 21, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Elise C. Kohn, Lance A. Liotta